Mosquito Cathepsin B-like Protease Involved in Embryonic Degradation of Vitellin Is Produced as a Latent Extraovarian Precursor*

Wen-Long ChoDagger , Shin-Mei TsaoDagger , Alan R. Hays§, Rosemarie Walter§, Jeng-Shong Chenparallel , Ekaterina S. Snigirevskaya**, and Alexander S. Raikhel§Dagger Dagger

From the Dagger  Department of Parasitology, National Yang-Ming University, Taipei 112, Taiwan, the § Department of Entomology, Michigan State University, East Lansing, Michigan 48824-1115, the  Programs in Genetics and Program in Cell and Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1115, and the ** Laboratory of Electron Microscopy, Institute of Cytology of the Russian Academy of Sciences, 194064 St. Petersburg, Russia

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Here we report identification of a novel member of the thiol protease superfamily in the yellow fever mosquito, Aedes aegypti. It is synthesized and secreted as a latent proenzyme in a sex-, stage-, and tissue-specific manner by the fat body, an insect metabolic tissue, of female mosquitoes during vitellogenesis in response to blood feeding. The secreted, hemolymph form of the enzyme is a large molecule, likely a hexamer, consisting of 44-kDa subunits. The deduced amino acid sequence of this 44-kDa precursor shares high similarity with cathepsin B but not with other mammalian cathepsins. We have named this mosquito enzyme vitellogenic cathepsin B (VCB). VCB decreases to 42 kDa after internalization by oocytes. In mature yolk bodies, VCB is located in the matrix surrounding the crystalline yolk protein, vitellin. At the onset of embryogenesis, VCB is further processed to 33 kDa. The embryo extract containing the 33-kDa VCB is active toward benzoyloxycarbonyl-Arg-Arg-para-nitroanilide, a cathepsin B-specific substrate, and degrades vitellogenin, the vitellin precursor. Both of these enzymatic activities are prevented by trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-64), a thiol protease inhibitor. Furthermore, addition of the anti-VCB antibody to the embryonic extract prevented cleavage of vitellogenin, strongly indicating that the activated VCB is involved in embryonic degradation of vitellin.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cathepsin B is a thiol (cysteine) protease with both endopeptidase and peptidyldipeptidase activities. Due to its broad specificity, cathepsin B plays a key role in intracellular protein catabolism in the lysosomal system (1). Cathepsin B has been well characterized both enzymatically and molecularly (2-10). The mammalian cathepsin B has been implicated in tumor invasion, progression, and metastasis (11-15). Tumor-specific cathepsin B is secreted by malignant cells as a latent high molecular weight precursor, presumably activated at cell contacts (16, 17).

In addition, cathepsins B, as well as the related cathepsins L, have been identified in numerous parasitic protozoa and helminthes, including prevalent pathogens of human and domestic animals (18-26). In the blood-sucking bug, Rhodnius prolixus, cathepsin B is the major gut proteolytic enzyme (27). In these organisms, cathepsins B and L are presumably involved in the degradation of host hemoglobin.

In insects and other arthropods, cathepsins B and L also participate in key developmental processes. In the flesh fly, Sarcophaga peregrina, hemocytes produce the extracellular form of a cathepsin B-like enzyme that participates in decomposition of the larval fat body during metamorphosis (28-30). Moreover, cathepsins B and L have been implicated in degradation of yolk proteins during embryonic development (31-41).

The elucidation of developmental mechanisms in the mosquito is important because this insect transmits the most devastating of vector-borne human diseases, including malaria, lymphatic filariasis, Dengue fever, and many others. Little is known, however, about the process of yolk protein degradation in the mosquito embryo. Previously, we have found that during vitellogenesis, the female fat body, a metabolic tissue analogous to the vertebrate liver, synthesizes and secretes a latent proenzyme of a serine carboxypeptidase which is homologous to yeast carboxypeptidase Y (42, 43). This 53-kDa proenzyme, which we named vitellogenic carboxypeptidase (VCP),1 is specifically accumulated by developing oocytes and deposited in yolk bodies. Although we have demonstrated that VCP is activated during embryogenesis, its role remains unknown.

In this paper we report the discovery of an unusual cathepsin-B-like thiol protease from the mosquito, Aedes aegypti. Similar to VCP, this enzyme is produced by the fat body of vitellogenic female mosquitoes in response to blood feeding. The cDNA encoding this unique mosquito enzyme, which we named vitellogenic cathepsin B (VCB), exhibits high similarity to vertebrate cathepsin B. VCB is secreted by the fat body as a latent proenzyme, similar in size to the latent tumor cathepsin B (44-kDa); it is accumulated by developing oocytes, where it is stored in yolk bodies. For the embryogenesis, VCB is processed to 33 kDa, similar in size to the activated single chain mammalian cathepsin B (16, 17). We have demonstrated that the embryo extract containing the 33-kDa VCB is active against benzoyloxycarbonyl-Arg-Arg-para-nitroanilide (Z-Arg-Arg-pNA), a cathepsin B-specific substrate, and degrades vitellogenin (Vg), a yolk protein precursor. Both enzymatic activities are prevented by trans-epoxysuccinyl -L-leucylamido-(4-guanidino)butane (E-64), a thiol protease inhibitor. Furthermore, addition of the anti-VCB antibody to the embryonic extract prevented cleavage of vitellogenin, strongly indicating that the activated VCB is involved in embryonic degradation of vitellin.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reagents-- All analytical grade chemicals and protease inhibitors were purchased from Sigma and Calbiochem, respectively, unless stated otherwise. [32P]dATP (3,000 Ci/mmol) and [35S]dATP were obtained from NEN Life Science Products Inc., while [35S]methionine (1,120 Ci/mmol) was from ICN Radiochemicals. DEAE-Sepharose was purchased from Pharmacia Biotech Inc. Bio-Rad was the source for protein assay reagents, econo-Pac desalting columns, and molecular weight standards for electrophoresis. Safety Solve II scintillation mixture was supplied by Research Product International. Paraformaldehyde, glutaraldehyde, and LR White were obtained from Polyscience, and protein-A-colloidal gold conjugates from E-Y Laboratories.

Animals-- Mosquitoes, A. aegypti, were reared as described previously (42). Three to five days after eclosion adult females were fed on white rats to initiate vitellogenesis. Mosquitoes were dissected in TES-buffered Aedes physiological saline (44) at room temperature.

Protein Preparation and Electrophoresis-- Fat body, ovarian, and embryonic proteins were prepared as described previously (42) in B3 buffer containing 25 mM TES, pH 7.5, 150 mM NaCl, 10% glycerol, 10 mM EDTA. Unless otherwise noted, all solutions contained the following inhibitors: 1 mM 4-(2-aminoethyl)-benzenesulfonylfluoride, HCl (AEBSF) (Calbiochem), 1 mM phenylmethylsulfonyl fluoride (PMSF) (Roche Molecular Biochemicals), 5 mM epsilon -amino-n-caproic acid, 1 mM benzamidine, 10 mM EDTA, 10 µg/ml aprotinin, and 2 µg/ml each antipain, leupeptin, pepstatin (Roche Molecular Biochemicals), and chymostatin. Fat body-secreted proteins were collected in TES-buffered Aedes physiological saline supplemented with aprotinin, to which the remainder of the inhibitors was added upon harvesting.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was done using either a 10% or 12% straight gel by the method of Laemmli (45) in vertical slab gels. Proteins were visualized by staining with either Coomassie Brilliant Blue R-250 or silver, or were processed for fluorography.

Nonreducing native polyacrylamide gel electrophoresis was performed using 3.5-25% acrylamide gradient gels cross-linked with 2.6% methylene bisacrylamide (46-48). The native PAGE sample buffer contained 125 mM Tris-HCl, pH 6.8, 12% glycerol, and 15 µM bromphenol blue. Gels were run for 18-21 h at 125 volts at 4 °C.

In Vitro Protein Labeling-- The in vitro culture of fat body and ovaries was as described previously (42). Synthesized and secreted fat body proteins were radiolabeled by incubating 3 female or 6 male fat bodies at 27 °C in 50 µl of TES-buffered culture media modified (49, 50) to contain the appropriate concentration of [35S]methionine (pulse media). If only pulse media was needed, fat bodies were incubated for 3 h.

Ovary-synthesized proteins were labeled in vitro by placing five pairs of ovaries (18 h post-blood meal) into 100 µl of TES-buffered culture media (51, 52) with [35S]methionine replacing unlabeled methionine. The ovaries were removed after 2.5 h, rinsed 3 times in APS and frozen at -80 °C.

Amino Acid Sequence Analysis-- The proteins, prepared as described above for antibody production, were electroblotted onto polyvinylidene difluoride membrane (0.2 µm pore size; Bio-Rad). The 44- and 42-kDa bands were excised from the blots of fat body-secreted and ovarian protein, respectively. The blots were sent to Harvard Microchem (Harvard University) for tryptic digestion and amino acid sequence analysis.

Cloning of VCB cDNA-- The probe used for screening a cDNA library for VCB was generated by PCR. RNA was isolated from fat bodies of 24-h post-blood fed female mosquitoes. cDNA was synthesized from the fat body mRNA and used as the template for PCR. An antisense degenerate primer was constructed from a portion of an internal peptide sequence, MADVEDL, obtained from microsequencing a tryptic fragment of the 44-kDa fat body-secreted VCB. The sequence of the first primer was: ATGGC(A/T/G/C)GA(T/C)GT(A/T/G/C)GA(A/G)GA(T/C)(T/C)T. The second primer was a 17-mer d(T). The resulting PCR product was subcloned into a pGEM-T vector for sequencing. The confirmed VCB fragment was used to screen a mosquito vitellogenic fat body cDNA library which was constructed at the EcoRI site of the lambda Zap II vector (Stratagene). The conditions for reverse transcription, PCR amplification, and cDNA cloning were previously described (53, 54). The method of enzymatic sequencing utilized was that reported by Sanger et al. (55).

DNA Analysis and Alignment-- The putative signal peptide in the deduced amino acid sequence was determined according to Kyte and Doolittle (56). The deduced amino acid sequence was analyzed by FastA, Motifs, and Gap programs of Genetics Computer Group software (University of Wisconsin, WI).

Isolation of RNA and Northern Blot Hybridization-- Total RNA was prepared using the guanidine isothiocyanate method (57-59). For Northern blot analyses, total RNA and RNA markers (Life Technologies) were separated by electrophoresis in 1.2% agarose formaldehyde gels. The RNA was transferred to a nitrocellulose membrane and hybridized to 32P-labeled probes. The conditions of hybridization at high stringency were used according to Cho et al. (60). A 255-bp EcoRI-HincII fragment located at the 5'-end of the VCB cDNA was used as a probe.

As a control for RNA loading, the cytoplasmic actin 5C gene of A. aegypti was used to probe the mosquito actin mRNA. Cloning of mosquito actin cDNA was described previously (61).

In Vitro Transcription and Translation-- For in vitro transcription and translation, the entire VCB cDNA was subcloned into pGEM 7Z(+) (Promega) under control of the SP6 promoter. Plasmid DNA was purified by the Wizard Minipreps DNA Purification System (Promega). Two micrograms of purified plasmid DNA were used for transcription and translation in the SP6 TNT Coupled Reticulocyte Lysate system (Promega). [35S]Methionine was used to label the translated product. All protocols were followed as described by the manufacturer.

Antibody Production-- Ovaries dissected from A. aegypti 28 h after blood feeding were processed and subjected to DEAE-Sepharose anion-exchange chromatography (51). Proteins in the Vn-free unbound fraction were separated by preparative SDS-PAGE. A band containing VCB (42 kDa) was excised and electroeluted using an ISCO model 1750 Electrophoretic Concentrator according to recommendations of the manufacturer. The elute provided the source of antigen to produce antibodies to this peptide (VCB-Ab1). Rabbits were injected with antigen/adjuvant (TiterMax, CytRx) two times at a 1-month interval. Serum proteins from the immunized rabbit were precipitated with ammonium sulfate at 35% of saturation and reconstituted at 5 mg/ml.

To avoid possible cross-hybridization with other cathepsins B, an Escherichia coli-expressed fusion protein, containing the VCB 20-kDa N-terminal region was used for production of another polyclonal antibody (VCB-Ab2). This VCB region contained the signal peptide, the entire propeptide, and an N-terminal portion of the mature VCB, which was less conserved that the rest of the protein. The antibody production was conducted as described for VCB-Ab1. Polyclonal antibodies against VCP and the Vg large subunit as well as monoclonal antibodies against Vg small subunit were already available (42, 62).

Immunoblots and Immunoprecipitation-- Proteins from SDS-PAGE and native PAGE gels were transferred to BA-S 83 supported nitrocellulose (Schleicher and Schuell) as described previously (48). Immunopositive bands were detected with the ECL Western blotting detection system (Amersham). Prior to immunoprecipitation, Vn or Vg were partially removed from ovarian extracts or fat body secretions, respectively, using a suspension of DEAE-Sepharose CL-6B as described previously (42). After removal of Vn or Vg, VCB was immunoprecipitated with anti-VCB antibodies. Protein A-Sepharose was added as a precipitating agent (42). After immunoprecipitation, the resulting pellet was washed and used in radioimmunoassay or SDS-PAGE and fluorography experiments (42).

Immunolabeling-- For immunocytochemical examination, tissues were fixed with 2% formaldehyde and 0.1% glutaraldehyde in 0.05 M sodium phosphate buffer, pH 7.4, for 45-60 min at room temperature. The specimens were then blocked with 100 mM glycine in the same buffer for 1 h at room temperature. For light immunocytochemistry, cryosections of 8 µm were applied on poly-L-lysine-coated slides and processed as described by Raikhel and Lea (63). The results were visualized by using phase-contrast and epifluorescence microscopy.

For electron microscopy, the tissues were dehydrated in ethanol and embedded in LR-White resin. The ultra-thin sections were prepared using an Ultracut E microtome (Reichert-Jung) and mounted on formvar-coated or uncoated nickel grids. The labeling was carried out on drops of reagents as described previously (64). Double labeling was performed according to the two-side method (65, 66). The controls included substitution of primary antibody by nonimmune rabbit IgG and the omission of primary antibodies followed by normal staining procedures. After immunolabeling, the sections were stained with uranyl acetate and lead citrate and examined with a JEOL 100CX II transmission electron microscope.

Enzyme Assay-- For enzymatic assay, embryos, 12-48 h after egg deposition, were extracted in B3 buffer containing 1 mM PMSF, 1 mM AEBSF, and 5 µM pepstatin. Each enzymatic reaction received 38 µg of total protein of embryonic extract. All enzymatic reactions were performed in duplicate using the MES buffer, pH 5.5, containing 100 mM MES, 1 mM PMSF, 1 mM AEBSF, 5 µM pepstatin, and 2.5 mM EDTA. Enzymatic assays were initiated by the addition of 81.1 mM Z-Arg-Arg-pNA (Bachem Biosciences) in 100% methanol to the reaction mixture, yielding a final concentration of 1.6 mM substrate and 2% methanol. To study the effect of specific inhibitors, either E-64 or chymostatin were added to the protein mixtures in the following concentrations: 0.3, 0.6, 1.2, or 2.5 mM; the mixture was incubated for 20 min at 37 °C prior to the addition of the enzymatic substrate. The control reaction was preincubated without any inhibitor. Data were collected by measuring the absorbance at 405 nm with a spectrophotometer after 2.5 h. A standard curve of pNA was plotted and regressed by the linear least-squares method. This curve was used to calculate the amount of pNA liberated by enzymatic activity. In experiments to determine the optimum pH of the enzyme, a range of pH from 3.5 to 7.5 was used.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Identification of a Novel Yolk Protein Precursor from the Mosquito Fat Body-- Previous analysis of proteins synthesized and secreted by the vitellogenic mosquito fat body has revealed a polypeptide of 44 kDa, in addition to Vg and VCP; furthermore, the presence of a polypeptide of 42 kDa has been observed among proteins extracted from vitellogenic ovaries or newly laid eggs (42). Here, polyclonal antibodies were produced against the 42-kDa polypeptide that was gel-purified from the ovarian source (VCB-Ab1). Immunoblot analysis showed that these antibodies recognized not only the 42-kDa ovarian polypeptide but also the single polypeptide of 44 kDa from vitellogenic fat bodies and their secretions, thus confirming the immunological identity of these two polypeptides. The immunoreactive polypeptides were present in neither previtellogenic female fat bodies nor males (Fig. 1).


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 1.   Presence of VCB in tissues of the mosquito, A. aegypti. A, immunoblot analysis of mosquito tissue extracts using polyclonal antibodies to the ovarian 42-kDa form of VCB (VCB-Ab1). B, the same using preimmune serum. Lane 1, whole male; lane 2, previtellogenic female fat body; lane 3, vitellogenic female fat body, 20 h PBM; lane 4, in vitro secretion from vitellogenic fat bodies, 20 h PBM; lane 5, ovary, 24 h PBM. Notice the increased mobility of VCB in the ovary. Extracts of ovary or vitellogenic fat body and in vitro secretions were first treated with DEAE-Sepharose CL-6B to reduce the amount of Vn or Vg present before separation by SDS-PAGE and transfer to nitrocellulose. SDS-PAGE was performed in a 12% gel under reducing conditions. The molecular standards in order of decreasing molecular mass (in kDa) were phosphorylase b, bovine serum albumin, ovalbumin, carbonic anhydrase, and soybean trypsin inhibitor (Bio-Rad).

Amino acid sequences were obtained by microsequencing tryptic fragments of the 42-kDa ovarian polypeptide and the 44-kDa polypeptide from vitellogenic fat body secretions. These sequences were analyzed for protein similarity. The results indicated that microsequenced fragments from both 42- and 44-kDa polypeptides shared similarity with human and other vertebrate cathepsins B (data not shown).

Cloning and Analysis of the cDNA Encoding the 44-kDa Yolk Protein Precursor, Vitellogenic Cathepsin B-- A 863-bp cDNA fragment was obtained from the amplification of vitellogenic fat body RNA by the PCR technique using the degenerate primer derived from the 44-kDa polypeptide sequence and an oligo(dT) primer. Both ends of the fragment matched the PCR primer sequences, and an open reading frame showed high similarity to vertebrate cathepsin B (data not shown). This PCR fragment was subcloned into a pGEM-T vector and was subsequently used as a probe to screen the cDNA library prepared from the fat bodies of vitellogenic female mosquitoes.

Several positive clones were isolated from the cDNA library, all of which measured approximately 1.3 kb and shared identical restriction maps. Partial sequencing of these clones showed they contained a sequence identical to that of the PCR fragment. The longest clone was sequenced from both strands. This cDNA clone of 1,239 bp contained an open reading frame of 1,158 nucleotides. It had an unusual putative polyadenylation signal, ATTAAA, reported previously (67, 68), located 20 bp upstream of the poly(A) tail (Fig. 2). The cDNA clone encoded a prepro-protein of 386 amino acid residues with a predicted size of 43,069 Da. The two sequences determined by direct microsequencing of the ovarian 42-kDa VCB and the fat body 44-kDa VCB were both found in its deduced amino acid sequence (Fig. 2). Hydropathy analysis (56) revealed that the protein was hydrophilic, possessing a strongly hydrophobic putative signal peptide of 16 residues (Fig. 2); moreover, the protein was expected to be positively charged with an isoelectric point (pI) of 7.95. However, in light of two potential N-linked glycosylation sites (69) and 10 potential phosphorylation sites (70) in the deduced VCB amino acid sequence, the fully processed protein could differ in its net charge (Fig. 2).


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 2.   Nucleotide and deduced amino acid sequences of vitellogenic cathepsin B from the mosquito, A. aegypti. The deduced amino acid sequence of the prepro-enzyme is displayed in capital letters. Both nucleotides and deduced amino acids are numbered. A putative signal peptide is marked by a thick underline. A potential pro-enzyme cleavage site is indicated by a solid triangle. Predicted N-linked glycosylation sites (N) are marked by squares. Potential phosphorylated serines (S) and threonines (T) are circled. Amino acids corresponding to the thiol protease conserved domains are boxed, and their catalytic residues are in reverse phases. The deduced amino acid sequences matching that obtained by direct peptide sequencing of 44-kDa peptide secreted from the fat body is underlined by a double line, and to that of 42-kDa ovarian protein is underlined by a dashed line. A polyadenylation signal ATTAAA is in bold.

To verify its identity, the 1.3-kb cDNA clone was expressed using a coupled in vitro transcription/translation system. A single polypeptide of the predicted size, 43 kDa, was immunoprecipitated from the translation reaction by the VCB-Ab1 antibodies, prepared against ovarian 42-kDa polypeptide (Fig. 3). Furthermore, in the presence of canine microsomal membranes, the expressed polypeptide increased to 44-kDa, identical in size to the 44-kDa VCB secreted by the fat body (Fig. 3). The 1.3-kb cDNA clone was also used as a probe for Northern hybridization. It hybridized strongly only to 1.3-kb mRNA from the fat body of vitellogenic female mosquitoes (see below). Taken together, these data confirm that the 1.3-kb cDNA encodes the 44-kDa fat body precursor of the ovarian 42-kDa VCB.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   Analysis of [35S]methionine-labeled products of in vitro expression of a mosquito VCB cDNA by a coupled transcription and translation system (Promega). Lane 1, the 1.3-kb VCB fragment subcloned in pGEM 7Z(+) were transcribed and translated in vitro. Lane 2, the same reaction conducted in the presence of canine microsomal membranes (Promega). Translation products were analyzed by SDS-PAGE in 12.5% gels under reducing conditions and fluorography. The molecular standards are as described in the legend to Fig. 1.

Mosquito 44-kDa Yolk Protein Precursor (VCB) Is a Proenzyme Homologous to Cathepsin B-- The deduced amino acid sequence of VCB exhibited high similarity to the family of eukaryotic thiol proteases, particularly the mammalian cathepsins B and cathepsin B-like proteases of invertebrates (Fig. 4). However, it shared only limited similarity to other cathepsins and related proteases, such as papain (not shown). The multiple alignment of homologous thiol proteases predicted that a putative start of the mature VCB occupied position Leu-125 (Figs. 2 and 4). Furthermore, three active sites characteristic for cathepsin B were conserved in VCB at positions Cys-150, His-315, and Asn-335 (Figs. 2 and 4). In addition, from six disulfate bonds typical for thiol proteases (4), the cysteine positions of five putative bonds were conserved in VCB.


View larger version (94K):
[in this window]
[in a new window]
 
Fig. 4.   Alignment of the deduced amino acid sequence of mosquito VCB with other thiol proteases. Asterisks mark the consensus residues of enzyme active sites (*). Conserved amino acids are marked by black boxes. Paired numbers under the sequences denote the locations of cysteine residues that form a disulfide bond. Abbreviations are: AaVCB, A. aegypti VCB; HsCtB, human cathepsin B, Homo sapiens (3); RnCtB, rat cathepsin B, Rattus norvegicus (3); BtCtB, bovine cathepsin B, Bos taurus (87); MmCtB, mouse cathepsin B, Mus musculus (3); Sp29K, 29-kDa protease of the blowfly, S. peregrina (30); SjCtB, trematode cathepsin B, Schistosoma japonicum (25); SmCyP, trematode cysteine protease, S. mansoni (20); HcCy1, nematode gut thiol protease 1, Hemonchus contortus (21); HcCy2, nematode thiol protease 2, H. contortus (23); CeCy1, nematode gut-specific cysteine protease, Caenorhabditis elegans (88). The descent rank of similarity to mosquito VCB was determined by Initn index of FastA (Genetics Computer Group software).

In contrast to mature enzymes (Fig. 4), the pro-peptide portion of VCB exhibited no significant similarity to those of cathepsins B (data not shown). Interestingly, however, similar to mammalian cathepsin B, the mosquito VCB pro-peptide has one putative glycosylation site, while the cathepsin B-like proteases of other invertebrates have none (Fig. 2).

Mosquito VCB Is a Fat Body-specific Protein Produced in Vitellogenic Females in Response to a Blood Meal-- Use of the entire VCB cDNA clone as a probe in the Northern blot analyses revealed a 1.3-kb transcript specific to vitellogenic fat bodies; additionally, weak hybridization to a slightly smaller mRNA band was observed in all other tested tissues (data not shown). This trace hybridization was likely due to partial similarity shared by VCB and other thiol proteases possibly of lysosomal origin. However, the use of a 208-bp of 5'-end of VCB fragment including the 5'-end noncoding region and the prepro-portion of VCB as a probe resulted in hybridization only to the 1.3-kb transcript from vitellogenic fat bodies (Fig. 5). Thus, Northern blot analyses confirmed the data we obtained at the protein level and demonstrated that the VCB gene was expressed exclusively in the fat body of vitellogenic female mosquitoes (Fig. 5). The 1.3-kb VCB transcript appeared in the fat body only after blood feeding, indicating that similarly to yolk protein precursors, it was initiated in response to a blood meal. The levels of the 1.3-kb VCB transcript reached a peak between 18 and 24 h PBM and then gradually declined. The message was not detected in the fat bodies at the end of vitellogenic cycle, 42 and 48 h PBM (Fig. 6).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 5.   Northern blot analysis of gene expression of mosquito VCB. Twenty micrograms of total RNA from different sexes, tissues, and stages were separated by a 1.2% agarose gel and stained with ethidium bromide (A). After photography, the gel was transferred to a nitrocellulose membrane and hybridized with a 32P-labeled 208-bp 5'-end fragment of the VCB cDNA, including the noncoding region and the prepro-portion of VCB (B). Lane 1, whole male; lane 2, vitellogenic female midgut, 24 h PBM; lane 3, vitellogenic female ovary, 24 h PBM; lane 4, pre-vitellogenic female fat body; lane 5, vitellogenic female fat body, 24 h PBM; lane 6, post-vitellogenic female fat body, 48 h PBM. RNA markers (Bio-Lab) are shown to the left in A.


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 6.   VCB RNA kinetics in the mosquito fat body. For each time point, total RNA (20 µg) extracted from the fat body was resolved in a 1.2% formaldehyde gel. A, the ethidium bromide stained gel. B, Northern hybridization with a 32P-labeled 208-bp VCB specific probe. Lane 1, pre-vitellogenic female fat body; lanes 2-9, vitellogenic female fat bodies: lane 2, 6 h PBM; lane 3, 12 h PBM; lane 4, 18 h PBM; lane 5, 24 h PBM; lane 6, 30 h PBM; lane 7, 36 h PBM; lane 8, 42 h PBM; lane 9, 48 h PBM. RNA markers (Bio-Lab) are shown to the left in A.

The secretory activity of the fat body with respect to production of yolk protein precursors was evaluated by pulse labeling using [35S]methionine for 1 h and collecting the chase media secretions for analysis. VCB secretion was monitored by VCB-Ab1 antibodies. As a control, anti-VCP antibodies were used to trace secretion of this yolk protein precursor. The data from these analyses showed that the kinetics of VCB secretion by the fat body were similar to those of VCP (Fig. 7). Both yolk protein precursors were detected at 4 h after initiation of vitellogenesis by a blood meal. Their synthesis and secretion increased rapidly to a maximum at 24-h post-blood meal, declined to a very low level by 36 h, and reached almost background level by 48 h (Fig. 7).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 7.   Time course of VCB secretion by fat bodies of female mosquitoes. Abdominal wall with adhering fat body of vitellogenic females at various stages of vitellogenesis, initiated by a blood meal, were incubated in culture medium in the presence of [35S]methionine for 1 h and chased for 1 h in isotope-free medium. Chase media samples were immunoprecipitated using polyclonal antibodies to 42-kDa VCB (VCB-Ab1) or to VCP and analyzed as described under "Materials and Methods." Data are expressed as counts/min of [35S]methionine-labeled protein per hour from three fat bodies.

Western blot analyses of the VCB protein in the fat body, utilizing either VCB-Ab1 or VCB-Ab2 antibodies, revealed a 44-kDa protein profile similar to that of secreted VCB, indicating that like yolk protein precursors, Vg and VCP, VCB was not stored in the fat body after its synthesis and was immediately secreted into the hemolymph (not shown). Both VCB-Ab1 and VCB-Ab2 antibodies recognized the same 44-kDa protein band in fat body preparations at all stages of vitellogenesis when the VCP gene was expressed (not shown).

VCB Is Localized in Fat Body Cell's Secretory and Oocyte's Endocytotic Organelles-- Previously (66) we utilized the VCB-Ab1 antibodies (designated there as anti-44KP antibodies) for localization of VCB. In this work we compared the localization of VCB by VCB-Ab2, produced against the recombinant VCB, with that by VCB-Ab1, produced against purified ovarian 42-kDa peptide. Fluorescent immunohistochemical analyses using either VCB-Ab1 or VCB-Ab2 antibodies demonstrated that VCB was localized only in the vitellogenic fat body and ovary after a blood meal (Figs. 8 and 9). In both tissues, the distribution of VCB was similar to that of VCP (42). Of particular interest was localization of VCB in the ovary, where it was seen surrounding the yolk granules (Fig. 9B).


View larger version (99K):
[in this window]
[in a new window]
 
Fig. 8.   Immunohistochemical localization of VCB in vitellogenic fat body, 18 h PBM. A, a phase-contrast image of the fat body. B, an immunofluorescent image of the same fat body stained with VCB-Ab2 polyclonal antibodies followed by fluorescein-conjugated goat anti-rabbit IgG. Magnification, × 400.


View larger version (90K):
[in this window]
[in a new window]
 
Fig. 9.   Immunohistochemical localization of VCB in the ovary, 18 h PBM. A, phase-contrast image of the ovarian follicle. B, an immunofluorescent image of the same ovarian follicle stained with VCB-Ab2 polyclonal antibodies followed by fluorescein-conjugated goat anti-rabbit IgG. Arrowheads show the VCB staining pattern as a rim around yolk bodies. Magnification, × 400.

The subcellular distribution of VCB, immunocytochemistry at the electron microscopic level, was used to localize VCB in the vitellogenic fat body and ovary. In the fat body cells, the trophocytes, VCB was present in the organelles of the secretory pathway: the Golgi complex and secretory granules. When double immunolabeling was performed utilizing antibodies for Vg, VCB, and protein A-colloidal gold particles of two different sizes, VCB was co-localized with Vg in these organelles, indicating the simultaneous processing of these proteins in the trophocyte's secretory system (Fig. 10).


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 10.   Co-localization of VCB and Vg in the Golgi complex (GC) and secretory granules (SG) of the fat body cell from a vitellogenic female mosquito (18 h PBM). VCB was localized using VCB-Ab1 antibodies and protein A-colloidal gold (15 nm); Vg was localized using polyclonal antibodies to the large Vg subunit and protein A-colloidal gold (10 nm). Magnification, × 100,000.

In vitellogenic ovarian follicles, which consist of the oocyte and nurse cells surrounded by follicle cells, VCB was present only in the oocyte's vesicles, endosomes, and yolk bodies (66). Simultaneous labeling for VCB and Vg demonstrated that these proteins were mixed in endosomes (66). However, localization of VCB differed dramatically in mature yolk bodies, where VCB was distributed as a narrow layer on the surface of the crystalline Vn, a storage form of Vg (Fig. 11). Morphologically, this area of the yolk body was visible as a non-crystalline matrix separating the crystalline yolk from the yolk body membrane. Double immunolocalization showed that in mature yolk bodies, this non-crystalline matrix was free of Vn, while, in contrast, the crystalline yolk was always free of VCB (66). The distribution of VCB in mature yolk bodies was similar in oocytes at the peak of endocytosis (24 h post-blood meal) and in those after termination of yolk accumulation (48 h post-blood meal).


View larger version (100K):
[in this window]
[in a new window]
 
Fig. 11.   Immunolocalization of VCB in the mature yolk body of a developing oocyte (18 h PBM). VCB-Ab1 polyclonal antibodies followed by protein A-colloidal gold (15 nm). Note that VCB, marked with 15-nm colloidal gold particles, is localized in the non-crystalline matrix of the yolk body. Magnification, × 50,000.

Correlation of Changes in the Native and Subunit Composition of VCB in the Ovaries and Eggs with Embryonic Development-- The processing of the 44-kDa hemolymph form of VCB in oocytes and eggs was monitored by immunoblot analysis and SDS-PAGE. In the oocyte, the internalized VCB reduced to 42 kDa; it remained unchanged for most of oocyte development; at 24 h PBM (Fig. 12, lane 1) in oocytes at the peak of protein uptake (51). However, in fully grown oocytes with completed protein yolk accumulation and nearly completed choriogenesis (87) at 48 h PBM, a 37-kDa band appeared which was recognized by either VCP-Ab1 or VCB-Ab2 antibodies (Fig. 12, lane 2). VCB further diminished to 33 kDa at the onset of embryogenesis in newly laid eggs (Fig. 12, lane 3). Immunoblot analyses utilizing either VCB-Ab1 or VCB-Ab2 showed that VCB was maintained as a 33-kDa polypeptide until the end of embryogenesis (Figs. 12 and 13). No immunopositive VCB bands were detected in extracts of newly hatched first instar larvae or later stages (Fig. 13).


View larger version (83K):
[in this window]
[in a new window]
 
Fig. 12.   Processing of VCB in the ovary and embryos. Lane 1, ovaries at the peak of Vg uptake, 24 h PBM; lane 2, ovaries with eggs nearly complete in their development, 48 h PBM; lane 3, 0-3 h post-oviposition eggs at the onset of embryonic development; lane 4, 48-h post-oviposition eggs during mid-embryogenesis; lane 5, 96-h post-oviposition eggs at the end of embryogenesis; lane 6, newly hatched first instar larva. Proteins were resolved by SDS-PAGE under reducing conditions in 12% gel. Proteins transferred onto a nitrocellulose membrane were probed by VCB-Ab1 antibodies. The molecular mass standards are as described in the legend to Fig. 1.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 13.   Western blot analysis of VCB in developing embryos. Lane 1, 0-12 h post-oviposition eggs; lane 2, 24-36 h post-oviposition eggs; lane 3, 48-60 h post-oviposition eggs; lane 4, 72-84 h post-oviposition eggs; lane 5, first instar larvae; lane 6, pupae. Protein extracts from oviposited eggs, larvae, and pupae were resolved with 10% SDS-PAGE, then subjected to Western blot hybridization using VCB-Ab2. The molecular mass standards are as described in the legend to Fig. 1.

Native PAGE and immunoblot analyses revealed that in the hemolymph, VCB existed as a high molecular weight molecule: its apparent size varied slightly depending on gel conditions within an average value of 236 ± 7 kDa (Fig. 15). The VCB native size decreased to 132 ± 4 kDa at the onset of embryonic development in the egg, when VCB was processed to its 33-kDa form; there was also a minor immunopositive band of 66 kDa present in the same preparation (Fig. 14).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 14.   Native molecular mass of hemolymph and embryonic forms of VCB. Lane 1, in vitro secretion from vitellogenic fat bodies 20 h PBM; lane 2, 48-hr post-oviposition eggs during mid-embryogenesis. Proteins were separated in a 3.5-25% gradient gel and transferred to nitrocellulose membrane. The blot was processed using VCB-Ab1 antibodies. The molecular standards in order of decreasing molecular mass (in kDa) were thyroglobulin, ferritin, catalase, lactate dehydrogenase, and bovine serum albumin (Pharmacia).

Mosquito VCB Is Activated in Embryos and Is Involved in Degradation of the Major Yolk Protein, Vitellin-- The processing of VCB to its 33-kDa form is reminiscent of the proteolytic activation of mammalian cathepsin B (71). To evaluate whether this VCB processing results in its enzymatic activation, we used Z-Arg-Arg-pNA, a substrate exhibiting specificity to cathepsin B (72). Secretions from vitellogenic fat bodies, containing 44-kDa VCB, did not exhibit appreciable cathepsin B enzymatic activity (data not shown). In contrast, protein extracts from embryos containing 33-kDa VCB showed significant cathepsin B activity (Fig. 15). Enzymatic activity was optimal at pH 5.5 (data not shown). This enzymatic activity, associated with embryonic extracts containing the 33-kDa VCB was highly sensitive to E-64. It showed partial sensitivity to chymostatin (Fig. 15).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 15.   Differential effect of inhibitors on enzymatic activity of VCB. The embryonic extract from 12- to 48-h post-oviposition eggs, containing 33-kDa VCB was examined for enzymatic activity with Z-Arg-Arg-pNA as described under "Materials and Methods." The reaction shown was performed for 60 min at pH 5.5. The inhibitors, E-64 and chymostatin, were added to the protein mixture at the final concentration indicated on the axis and preincubated for 20 min at 37 °C prior to the addition of the enzymatic substrate. The activity was expressed as micromolar pNA released from the substrate Z-Arg-Arg-pNA per µg of protein.

Next, we determined whether the processing of VCB to its 33-kDa form coincided with the beginning of vitellin (Vn) degradation. We applied immunoblot analysis using monoclonal antibodies against the Vg/Vn small 66-kDa subunit (Fig. 16A) and polyclonal antibodies against the Vg/Vn large 200-kDa subunit (Fig. 16B). The immunoblot analysis of Vn in the ovary and embryos of the same stages as in Fig. 12 showed that clear signs of Vn cleavage were evident only in embryos, coinciding with the processing of VCB to the 33-kDa form. Interestingly that the large Vn subunit exhibited a degradation pattern earlier than the small Vn subunit (Fig. 16, A and B, lanes 3 and 4). However, both Vn subunits were completely degraded by the end of embryonic development (Fig. 16, lanes 6).


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 16.   Vn degradation during mosquito embryonic development. A, immunoblot analysis using monoclonal antibodies against the Vg/Vn small 66-kDa subunit; B, using polyclonal antibodies against the Vg/Vn large 200-kDa subunit. Lanes 1, ovaries at the peak of Vg uptake, 24 h PBM; lanes 2, ovaries with eggs nearly complete in their development, 48 h PBM; lanes 3, 0-3 h post-oviposition eggs at the onset of embryonic development; lanes 4, 48-h post-oviposition eggs during mid-embryogenesis; lanes 5, 96-h post-oviposition eggs at the end of embryogenesis; lanes 6, newly hatched first instar larva. The molecular standards in order of decreasing molecular mass (in kDa) were myosin, beta -galactosidase, phosphorylase b, bovine serum albumin, ovalbumin, carbonic anhydrase, and soybean trypsin inhibitor (Bio-Rad).

To ascertain whether the cathepsin B activity detected in mosquito embryos is linked to Vn degradation, purified Vg, labeled with [35S]methionine was incubated with embryonic protein extracts containing the 33-kDa VCB (Fig. 17). The results of the SDS-PAGE analyses showed that under these conditions, Vg was degraded. Importantly, Vg degradation was entirely inhibited by addition of E-64 to the protein mixture (Fig. 17, lane 3); however, protease inhibitors specific to serine, aspartic, and metalloproteinases were not effective in inhibiting Vg degradation (Fig. 17, lanes 1, 2, and 4). In the next experiment, [35S]methionine-labeled Vg was incubated with embryonic protein extracts containing the 33-kDa VCB in the presence of increasing concentrations of VCB-Ab1 antibodies (Fig. 18, lanes 4-6). Control samples were incubated with the same amounts of either preimmune IgG (Fig. 18, lanes 7-9) or bovine serum albumin (Fig. 18, lanes 10-12). At the concentration of 0.5 µg/µl, the specific anti-VCB antibodies almost entirely inhibited cleavage of Vg (Fig. 18, lane 6). The same amounts of preimmune IgG in the solution had negligible effect of Vg degradation (Fig. 18, lane 9), while bovine serum albumin had no effect (Fig. 18, lane 12).


View larger version (62K):
[in this window]
[in a new window]
 
Fig. 17.   Degradation of vitellogenin by embryonic extract (12 to 48 h post-oviposition eggs) containing 33-kDa VCB. Purified [35S]methionine-labeled Vg was incubated with the embryonic extract at pH 4.0 and resolved by SDS-PAGE in a 10% gel under reducing conditions. Lane 1, the reaction was performed in the presence of serine protease inhibitors, 1 mM PMSF and 1 mM AEBSF; lane 2, in the presence of 5 µM pepstatin, an inhibitor of aspartic proteases; lane 3, in the presence of 2.5 µM E-64, an inhibitor of thiol proteases; lane 4, PMSF, AEBSF, and pepstatin; lane 5, all listed protease inhibitors; lane 6, incubation of Vg without the embryonic extract, at pH 4.0; lane 7, Vg sample without any treatment. VgL, 200-kDa large Vg subunit; VgS, 66-kDa small Vg subunit. The molecular mass standards are as described in the legend to Fig. 16.


View larger version (59K):
[in this window]
[in a new window]
 
Fig. 18.   Degradation of vitellogenin by embryonic extract (12-48 h post-oviposition eggs) containing 33-kDa VCB. Purified [35S]methionine-labeled Vg was incubated with the embryonic extract at pH 5.35 in the presence of 1 mM PMSF, 1 mM AEBSF, 5 µM pepstatin, and 2.5 mM EDTA. Proteins were resolved by SDS-PAGE in a 10% gel under reducing conditions. Lane 1, Vg sample without any treatment; lane 2, incubation of Vg in thee presence of 2.5 µM E-64, an inhibitor of thiol proteases; lane 3, incubation of Vg without the embryonic extract, at pH 5.35; lanes 4-6, incubation of Vg in the presence of increasing concentrations of VCB-Ab1 antibodies; lanes 7-9, preimmune rabbit IgG; lanes 10-12, bovine serum albumin; concentrations of VCB-Ab1, IgG, and bovine serum albumin in each of thee lanes were 0.125, 0.25, and 0.5 µg/µl, respectively. The molecular mass standards are as described in the legend to Fig. 1.

To test whether or not pro-VCB is processed and activated under acidic conditions, as are mammalian cathepsins B (7, 73), the secretory 44-kDa and ovarian 42-kDa forms of VCB were incubated under different acidic pH conditions (4.0 and 5.5). After treatment with acidic pH, the 44-kDa pro-VCB neither catalyzed the substrate Z-Arg-Arg-pNA (Fig. 19A, line 1) nor degraded [35S]methionine-labeled Vg (not shown). Immunoblot analysis showed that the 44-kDa pro-VCB was processed to a 35-kDa peptide but not to a 33-kDa one (Fig. 19B, lanes 3 and 4). Unlike the 44-kDa pro-VCB, the ovarian extract, containing the 42-kDa VCB, exhibited cathepsin B activity after treatment with acidic pH (Fig. 19A). The immunoblot revealed that VCB was processed to a 33-kDa form (Fig. 19B, lane 5). VCB processing was equally efficient at pH 4.0 and 5.5 and unaffected by the presence of protease inhibitors specific to serine, aspartic, and metalloproteinases (Fig. 19B).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 19.   Activation of mosquito VCB under acidic conditions. A, protein extracts supplemented with protease inhibitors (1 mM PMSF, 1 mM AEBSF, 5 µM pepstatin, and 2.5 mM EDTA) were incubated for the indicated times under the acidic (pH 4. 0 or 5.5) or control conditions (pH 7.5). Enzymatic activity was measured using Z-Arg-Arg-pNA as substrate. Activity is expressed as in Fig. 15. Line 1, fat body secretions; line 2, embryonic extracts from ovaries after the termination of yolk accumulation, 48 h PBM; line 3, protein extract from embryos, 12-48 h oviposition eggs. B, immunoblot analysis of activated VCB peptides. Immunoblot was performed as described in the legend to Fig. 1. Lane 1, fat body secretions, under the control conditions at pH 7.5; lane 2, embryonic extract under the control conditions; lane 3, fat body secretions under the acidic conditions at pH 4.0; lane 4, fat body secretions under acidic condition at pH 5.5, corresponds to the enzymatic reaction (line 1) in A; lane 5, protein extract from vitellogenic ovaries under acidic conditions at pH 5.5, corresponds to the enzymatic reaction (line 2) in A; lane 6, protein extract from embryos, 12-48 h post-oviposition eggs, under acidic conditions at pH 5.5, corresponds to the enzymatic reaction (line 3) in A.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In this paper, we report an unusual form of cathepsin B-like thiol protease from the mosquito, A. aegypti. Cloning and analysis of the cDNA encoding VCB demonstrated its high similarity to mammalian cathepsins B and invertebrate cathepsin B-like proteases, but not to other related cathepsins. The structural analysis of the deduced amino acid VCB sequence suggests that the folding and activity of this enzyme are likely similar to cathepsins B: the predicted start of mature VCB at Leu-125 was similar to mammalian cathepsins B; moreover, the active sites and cysteine positions of five putative disulfide bonds were conserved in VCB (Fig. 4).

The mosquito VCB was also observed to resemble mammalian cathepsins B in its size. It was secreted as a proenzyme of 44 kDa similar in size to the latent pro-cathepsin B secreted by malignant cells (71). Moreover, the 33-kDa embryonic form of VCB exhibited the same size as the active single chain cathepsin B (71).

The presence of the 33-kDa embryonic form of VCB was shown to correlate with activity characteristic of cathepsin B (72). This activity was highly expressed with the cathepsin-B-specific substrate, Z-Arg-Arg-pNA; it was sensitive to E-64, but considerably less to chymostatin.

The unique feature that we observed for this mosquito cathepsin-B-like enzyme was its exclusive synthesis and secretion by the fat body of vitellogenic female mosquitoes as a latent, high molecular size precursor consisting of five or six subunits with a molecular mass of 44 kDa. Its synthesis in the female fat body is initiated by blood feeding, and the kinetics of its secretion by the vitellogenic fat body are similar to those of the yolk protein precursors, Vg (59) and VCP (42, 43).

We established the link between the 44-kDa fat body-secreted hemolymph VCB and the 42-kDa ovarian VCB by using the anti-42-kDa VCB (VCB-Ab1) in immunoblotting analyses. The anti-VCB-specific antibodies, generated against the recombinant protein (VCB-Ab2), verified the identity of 44 and 42 kDa, and other processed peptides as well. Despite the large amounts of VCB present in the ovary, neither its mRNA nor synthesis were detected there. Thus, the fat body is the only source of the 44-kDa polypeptide as a precursor of the ovarian 42-kDa polypeptide, which suggests that its accumulation in the ovary occurs by endocytosis, similar to other yolk protein precursors (73). VCB immunolocalization in the ovary confirmed that this yolk protein precursor is internalized in developing oocytes via the endocytotic pathway. Interestingly, VCB is segregated from crystalline Vn in mature yolk bodies, the accumulative endocytotic organelle of the oocyte, being present only in the non-crystalline matrix surrounding Vn. In this matrix of mature yolk bodies, VCB is mixed with VCP (66). It is, therefore, likely that the presence of both these proenzymes in the matrix surrounding crystalline Vn enhances their rapid activation at the onset of embryonic development, the point at which yolk bodies undergo acidification. The latter event has been documented for both insects and vertebrates (74, 75).

The fat body-secreted hemolymph form of VCB is stable latent proenzyme which unlike mammalian cathepsins B (7, 76), cannot be activated by acidic pH alone. Here, the reduction of the hemolymph pro-VCB to 35 kDa (not 33-kDa) after treatment with acidic pH was not sufficient for enzyme activation. Clearly, an additional step or steps are required for the activation of the latent hemolymph pro-VCB. In our experiments, pro-VCB did not activate to the 33-kDa peptide itself in an in vitro transcription/translation system (Fig. 3), as has been reported for Schistosoma mansoni cathepsin-B-like cysteine protease (77). This stability of the hemolymph pro-VCB as a latent proenzyme prior to its internalization by developing oocytes is physiologically important. It may be additionally enhanced by the presence of the glycosylation site in its proenzyme portion.

After treatment with acidic pH, the ovarian extract containing the 42-kDa VCB exhibited enhanced cathepsin B activity. Significantly, under these conditions, most of the ovarian 42-kDa VCB was processed to the 33-kDa polypeptide. Although the nature of this processing event is unclear, the removal of 2 kDa from each VCB subunit apparently renders pro-VCB capable of activation by acidic pH after the onset of embryonic development. Although the activation reactions were performed using crude extracts, it is unlikely that the proteolytic processing of VCB by treatment with acidic pH was a function of another protease, as both the 44-kDa hemolymph and the 42-kDa ovarian VCB were processed to 35 and 33 kDa in the presence of protease inhibitors. Autocatalytic cleavage under acidic conditions, which has been reported for mammalian cathepsins B (7, 76), may be a possible mechanism for the activation of the 42-kDa VCB in the mosquito embryo.

The estimation of native molecular mass suggests that in the hemolymph, VCB exists as a hexamer or a pentamer of 44-kDa subunits (Fig. 14). A hexameric structure is characteristic for some insect hemolymph proteins (78). The feature of VCB may also increase its stability in the hemolymph; alternatively, it may be important for the recognition of VCB by oocyte receptors. Here, we found that at the onset of embryonic development, when VCB was processed to the active 33-kDa form, its native size was reduced to 132 kDa, which likely corresponded to a tetramer of 33-kDa subunits. The presence of a minor 66-kDa band indicated that at least some of the 33-kDa VCB were in dimer form (Fig. 14).

Our experiments utilizing 35S-labeled Vg as a substrate suggest that VCB likely plays a key role in the degradation of Vn, the major yolk protein in mosquito embryos. The embryonic extract containing the 33-kDa VCB displayed high activity to Vg digestion, and this degradation was blocked by E-64. Moreover, the specific anti-VCB antibodies almost entirely inhibited cleavage of Vg by the embryonic extract containing the 33-kDa VCB, strongly suggesting that VCB is the key enzyme in embryonic degradation of Vn in the mosquito embryo.

Proteases similar to cathepsins B and L have been shown to be active during embryonic development in a number of insects and other arthropods (31-40). Best studied is the cathepsin L-like cysteine protease from the silkworm, Bombyx mori (35-38): it is produced as a latent proenzyme of 47 kDa and processed under acidic conditions to a 39-kDa form, the active enzyme present in embryos. In addition to exhibiting enzymatic properties characteristic of cathepsin L-like cysteine proteases, this Bombyx protease shows high sequence similarity to mammalian cathepsin L. Importantly, the direct action of Bombyx cathepsin L-like cysteine protease on vitellin has been demonstrated. The cDNA encoding the proenzyme of this Bombyx cathepsin L-like cysteine protease has been cloned from the ovarian cDNA library. Furthermore, immunological analyses have shown that it is produced in the ovary by follicular cells and is then deposited in developing oocytes (35-38).

In Drosophila, cathepsin B-like protease is presumed to be maternally produced; however, its precise origin is not known (32). Previously, we demonstrated that mosquito VCP, one of the enzymes present in the yolk bodies, is secreted by the fat body (42; 43). Furthermore, immunological analyses have implicated the mosquito female fat body in the production of VCB (44KP) (66). For Blatella germanica, an immunocytochemical study has suggested that the fat body and follicular epithelium are the sources of the vitellin-processing protease (79). In this study, however, we provided solid molecular and biochemical proofs that the mosquito embryonic cathepsin B-like protease that we describe here is produced exclusively by the fat body as a yolk protein precursor.

In oviparous animals, extraovarian tissues play an important role in egg maturation by producing yolk protein precursors, which serve as a major nutritional source for developing embryos. The liver of oviparous vertebrates and the fat body of insects both produce large quantities of yolk protein precursors, which are subsequently internalized by developing oocytes and deposited in yolk bodies. The most abundant of these yolk protein precursors is Vg, a large glycophospholipoprotein conserved throughout evolution of invertebrate and vertebrate oviparous animals (80-83). In Lepidopteran insects, the fat body additionally produces a smaller yolk protein precursor, either microvitellogenin or the 30-kDa yolk protein (84-86).

In the mosquito, however, the proenzymes VCB and VCP are produced by the fat body as yolk protein precursors. The discovery that enzymes involved in the embryonic degradation of yolk proteins are produced as precursors by an extraovarian tissue is a new biological phenomenon previously unknown in insects or other oviparous animals. Moreover, the finding that one of these enzymes is a cathepsin B sheds light on yet another important mode of the utilization of this key protease.

    ACKNOWLEDGEMENTS

We thank Drs. T. Sappington, K. Deitsch, and A. Biran for critical reading of the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants AI-24716 and AI-32154 (to A. S. R.) and by National Science Council (Taiwan) 86-2314-B-010-065 (to W-L. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF127592.

parallel Present address: Novartis Seeds, 3054 Cornwallis Rd., Research Triangle Park, NC 27709-2257.

Dagger Dagger To whom correspondence should be addressed: Dept. of Entomology, S-150 Plant Biology Bldg., Michigan State University, East Lansing, MI 48824-1115. Tel.: 517-353-7144; Fax: 517-353-3396; E-mail: araikhel{at}pilot.msu.edu.

    ABBREVIATIONS

The abbreviations used are: VCP, vitellogenic carboxypeptidase; AEBSF, 4-(2-aminoethyl)-benzenesulfonylfluoride; E-64, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane; kb, kilobase pair(s); PBM, post-blood meal; PCR, polymerase chain reaction; PMSF, phenylmethylsulfonyl fluoride; PAGE, polyacrylamide gel electrophoresis; TES, 2-{[tris-1,1-bis(hydroxymethyl)ethyl]-amino}-ethanesulfonic acid; 20E, 20-hydroxyecdysone; VCB, vitellogenic cathepsin B; VCB-Ab1, polyclonal antibodies produced against ovarian 42-kDa VCB; VCB-Ab2, polyclonal antibodies produced against the recombinatly produced VCB; Vg, vitellogenin; Vn, vitellin; MES, 4-morpholineethanesulfonic acid; pNA, p-nitroanalide; bp, base pair(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Bond, J. S., and Butler, P. E. (1987) Annu. Rev. Biochem. 56, 333-364[CrossRef][Medline] [Order article via Infotrieve]
  2. Takio, K., Towatari, T., Katunuma, N., Teller, D. C., and Titani, K. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 3666-3670[Abstract]
  3. Chan, S. J., San Segundo, B., McCormick, M. B., and Steiner, D. F. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 7721-7725[Abstract]
  4. Musil, D., Zucic, D., Turk, D., Engh, R. A., Mayr, I., Huber, R., Popovic, T., Turk, V., Towatari, T., Katunuma, N., and Bode, W. (1991) EMBO J. 10, 2321-2330[Abstract]
  5. Béchet, D. M., Ferrara, M. J., Mordier, S. B., Roux, M. P., Deval, C. D., and Obled, A. (1991) J. Biol. Chem. 266, 14104-14112[Abstract/Free Full Text]
  6. Qian, F., Frankfater, A., Chan, S. J., and Steiner, D. F. (1991) DNA Cell Biol. 10, 159-168[Medline] [Order article via Infotrieve]
  7. Rowan, A. D., Mason, P., Mach, L., and Mort, J. S. (1992) J. Biol. Chem. 267, 15993-15999[Abstract/Free Full Text]
  8. Mach, L., Mort, J. S., and Glössl, J. (1994) J. Biol. Chem. 269, 13030-13035[Abstract/Free Full Text]
  9. Xing, R., Addington, A. K., and Mason, R. W. (1998) Biochem. J. 332, 499-505[Medline] [Order article via Infotrieve]
  10. Yu, Y., Vranken, W., Goudreau, N., de Miguel, E., Magny, M. C., Mort, J. S., Dupras, R., Storer, A. C., and Ni, F. (1998) FEBS Lett. 429, 9-16[CrossRef][Medline] [Order article via Infotrieve]
  11. Poole, A. R., Tiltman, K. J., Recklies, A. D., and Stoker, T. A. M. (1978) Nature 273, 545-547[Medline] [Order article via Infotrieve]
  12. Sloane, B. F., Dunn, J. R., and Honn, K. V. (1981) Science 212, 1151-1153[Medline] [Order article via Infotrieve]
  13. Mort, J. S., and Battle, D. J.. (1997) Int. J. Biochem. Cell Biol. 29, 715-720[CrossRef][Medline] [Order article via Infotrieve]
  14. Kim, K., Cai, J., Shuja, S., Kuo, T., and Murnane, M. J. (1998) Int. J. Cancer 79, 324-333[CrossRef][Medline] [Order article via Infotrieve]
  15. Khan, A., Krishna, M., Baker, S. P., and Banner, B. F. (1998) Mod. Pathol. 11, 704-708[Medline] [Order article via Infotrieve]
  16. Mort, J. S., and Recklies, A. D. (1986) Biochem. J. 233, 57-63[Medline] [Order article via Infotrieve]
  17. Sloane, B. F., Moin, K., Krepela, E., and Rozhin, J. (1990) Cancer Metastasis Rev. 9, 333-352[Medline] [Order article via Infotrieve]
  18. Cazzulo, J. J., Couso, R., Raimondi, A., Wernstedt, C., and Hellman, U. (1989) Mol. Biochem. Parasitol. 33, 33-42[CrossRef][Medline] [Order article via Infotrieve]
  19. Rosenthal, P. J., McKerrow, J. H., Rasnick, D., and Leech, J. H. (1989) Mol. Biochem. Parasitol. 35, 177-184[CrossRef][Medline] [Order article via Infotrieve]
  20. Klinkert, M. Q., Felleisen, R., Link, G., Ruppel, A., and Beck, E. (1989) Mol. Biochem. Parasitol. 33, 113-122[CrossRef][Medline] [Order article via Infotrieve]
  21. Cox, G. N., Pratt, D., Hageman, R., and Boisvenue, R. J. (1990) Mol. Biochem. Parasitol. 41, 25-34[Medline] [Order article via Infotrieve]
  22. Pratt, D., Cox, G. N., Milhausen, M. J., and Boisvenue, R. J. (1990) Mol. Biochem. Parasitol. 43, 181-192[Medline] [Order article via Infotrieve]
  23. Pratt, D., Boisvenue, R. J., and Cox, G. N. (1992) Mol. Biochem. Parasitol. 56, 39-48[CrossRef][Medline] [Order article via Infotrieve]
  24. Robertson, C. D., and Coombs, G. H. (1993) Mol. Biochem. Parasitol. 62, 271-280[Medline] [Order article via Infotrieve]
  25. Merckelbach, A., Hasse, S., Dell, R., Eschlbeck, A., and Ruppel, A. (1994) Trop. Med. Parasitol. 45, 193-198[Medline] [Order article via Infotrieve]
  26. Loukas, A., Selzer, P. M., and Maizels, R. M. (1998) Mol. Biochem. Parasitol. 92, 275-289[CrossRef][Medline] [Order article via Infotrieve]
  27. Terra, W. R., Ferreira, C., and Garcia, E. S. (1988) Insect Biochem. 18, 423-434[CrossRef]
  28. Kurata, S., Saito, H., and Natori, S. (1992) Dev. Biol. 153, 115-121[Medline] [Order article via Infotrieve]
  29. Kurata, S., Saito, H., and Natori, S. (1992) Eur. J. Biochem. 204, 911-914[Abstract]
  30. Takahashi, N., Kurata, S., and Natori, S. (1993) FEBS Lett. 334, 153-157[CrossRef][Medline] [Order article via Infotrieve]
  31. Medina, M., León, P., and Vallejo, C. G. (1988) Arch. Biochem. Biophys. 263, 355-363[Medline] [Order article via Infotrieve]
  32. Medina, M., and Valljo, C. G. (1989) Dev. Growth Differ. 31, 241-247
  33. Fagotto, F. (1990) Arch. Insect Biochem. Physiol. 14, 217-235[Medline] [Order article via Infotrieve]
  34. Fagotto, F. (1990) Arch. Insect Biochem. Physiol. 14, 237-252[Medline] [Order article via Infotrieve]
  35. Takahashi, S. Y., Yamamoto, Y., Shionoya, Y., and Kageyama, T. (1993) J. Biochem. (Tokyo) 114, 267-272[Abstract]
  36. Yamamoto, Y., and Takahashi, S. Y. (1993) Comp. Biochem. Physiol. 106, 35-45
  37. Yamamoto, Y., Takimoto, K., Izumi, S., Toriyama-Sakurai, M., Kageyama, T., and Takahashi, S. Y. (1994) J. Biochem. (Tokyo) 116, 1330-1335[Abstract]
  38. Yamamoto, Y., Zhao, X., Suzuki, A. C., and Takahashi, S. Y. (1994) J. Insect Physiol. 40, 447-454[CrossRef]
  39. Ribolla, P. E., Daffre, S., and de Bianchi, A. G. (1993) Insect Biochem. Mol. Biol. 23, 217-223[CrossRef]
  40. Liu, X., McCarron, R. C., and Nordin, J. H. (1995) J. Biol. Chem. 271, 33344-33351[Abstract/Free Full Text]
  41. Yoshizaki, N., Moriyama, A., and Yonezawa, S. (1998) Comp. Biochem. Physiol. Biochem. Mol. Biol. 119, 571-576[CrossRef]
  42. Hays, A. R., and Raikhel, A. S. (1990) Roux's Arch. Dev. Biol. 199, 114-121
  43. Cho, W. L., Deitsch, K. W., and Raikhel, A. S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10821-10824[Abstract]
  44. Hagedorn, H. H., Turner, S., Hagedorn, E. A., Pontecorvo, D., Greenbaum, P., Pfeiffer, D., Wheelock, D., and Flanagan, T. R. (1977) J. Insect Physiol. 23, 203-206[CrossRef][Medline] [Order article via Infotrieve]
  45. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  46. Ornstein, L. (1964) Ann. N. Y. Acad. Sci. 121, 321-349
  47. Davis, B. J. (1964) Ann. N. Y. Acad. Sci. 121, 404-427[Medline] [Order article via Infotrieve]
  48. Sappington, T. W., Hays, A. R., and Raikhel, A. S. (1995) Insect Biochem. Mol. Biol. 25, 807-817[CrossRef][Medline] [Order article via Infotrieve]
  49. Raikhel, A. S., Deitsch, K. W., and Sappington, T. W. (1997) in The Molecular Biology of Insect Disease Vectors. A Methods Manual (Crampton, J. M., Beard, C. B., and Louis, C., eds), pp. 507-522, Chapman & Hall, London
  50. Dhadialla, T. S., and Raikhel, A. S. (1990) J. Biol. Chem. 265, 9924-9933[Abstract/Free Full Text]
  51. Koller, C. N., Dhadialla, T. S., and Raikhel, A. S. (1989) Insect Biochem. 19, 693-702
  52. Sappington, T. W., Brown, M. R., and Raikhel, A. S. (1997) in The Molecular Biology of Insect Disease Vectors: A Methods Manual (Crampton, J. M., Beard, C. B., and Louis, C., eds), pp. 523-535, Chapman & Hall, London
  53. Cho, W.-L., Kapitskaya, M. Z., and Raikhel, A. S. (1995) Insect Biochem. Mol. Biol. 25, 19-27[CrossRef][Medline] [Order article via Infotrieve]
  54. Chiou, J.-Y., Huang, S.-J., Huang, S.-T., and Cho, W.-L. (1998) J. Biomed. Sci. 5, 120-126[Medline] [Order article via Infotrieve]
  55. Sanger, F., Nicklen, S., and Coulson, A. R. (1997) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467
  56. Kyte, J., and Doolittle, R. F. (1982) J. Mol. Biol. 157, 105-132[Medline] [Order article via Infotrieve]
  57. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. (1979) Biochemistry 18, 5294-5299[Medline] [Order article via Infotrieve]
  58. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[CrossRef][Medline] [Order article via Infotrieve]
  59. Cho, W. L., and Raikhel, A. S. (1992) J. Biol. Chem. 267, 21823-21829[Abstract/Free Full Text]
  60. Cho, W.-L., Fu, T.-F., Chiou, J.-Y., and Chen, C.-C. (1997) Insect Biochem. Mol. Biol. 27, 351-358[CrossRef][Medline] [Order article via Infotrieve]
  61. Deitsch, K. W., Chen, J. S., and Raikhel, A. S. (1995) Insect Biochem. Mol. Biol. 25, 449-454[CrossRef][Medline] [Order article via Infotrieve]
  62. Raikhel, A. S., Pratt, L., and Lea, A. O. (1986) J. Insect. Physiol. 32, 879-890
  63. Raikhel, A. S., and Lea, A. O. (1983) Tissue & Cell 15, 281-300[CrossRef][Medline] [Order article via Infotrieve]
  64. Raikhel, A. S. (1987) Tissue & Cell 19, 515-529[Medline] [Order article via Infotrieve]
  65. Bendayan, M. (1982) J. Histochem. Cytochem. 30, 691-696[Abstract]
  66. Snigirevskaya, E. S., Hays, A. R., and Raikhel, A. S. (1997) Cell Tissue Res. 290, 129-142[CrossRef][Medline] [Order article via Infotrieve]
  67. Brinke, A., Green, P. M., and Giannelli, F. (1997) Genomics 45, 105-112[CrossRef][Medline] [Order article via Infotrieve]
  68. Seroussi, E., Pan, H. Q., Kedra, D., Roe, B. A., and Dumanski, J. P. (1998) Gene (Amst.) 212, 13-20[CrossRef][Medline] [Order article via Infotrieve]
  69. Marshall, R. D. (1972) Annu. Rev. Biochem. 41, 673-702[CrossRef][Medline] [Order article via Infotrieve]
  70. Kuenzel, E. A., Mulligan, J. A., Sommercorn, J., and Kreb, E. G. (1987) J. Biol. Chem. 262, 9136-9140[Abstract/Free Full Text]
  71. Mach, L., Stüwe, K., Hagen, A., Ballaun, C., and Glössl, J. (1992) Biochem. J. 282, 577-582[Medline] [Order article via Infotrieve]
  72. Barrett, A. J., and Kirschke, H. (1981) Methods Enzymol. 80, 535-561[Medline] [Order article via Infotrieve]
  73. Raikhel, A. S., and Dhadialla, T. S. (1992) Annu. Rev. Entomol. 37, 217-251[CrossRef][Medline] [Order article via Infotrieve]
  74. Nordin, J. H., Beaudoin, E. L., and Liu, X. (1991) Arch. Insect Biochem. Physiol. 18, 177-192
  75. Fagotto, F., and Maxfield, F. R. (1994) J. Cell Biol. 125, 1047-1056[Abstract]
  76. Mach, L., Schwihla, H., Stüwe, K., Rowan, A. D., Mort, J. S., and Glössl, J. (1993) Biochem. J. 293, 437-442[Medline] [Order article via Infotrieve]
  77. Felleisen, R., and Klinkert, M. Q. (1990) EMBO J. 9, 371-377[Abstract]
  78. Telfer, W. H., and Kunkel, J. G. (1991) Annu. Rev. Entomol. 36, 205-228[CrossRef][Medline] [Order article via Infotrieve]
  79. Giorgi, F., Yin, L., Cecchettini, A., and Nordin, J. H. (1997) Tissue & Cell 29, 293-303
  80. Wahli, W. (1988) Trends Genet. 4, 227-232[CrossRef][Medline] [Order article via Infotrieve]
  81. Byrne, B. M., Gruber, M., and AB, G. (1989) Progr. Biophys. Mol. Biol. 53, 33-69[CrossRef][Medline] [Order article via Infotrieve]
  82. Chen, J. S., Sappington, T. W., and Raikhel, A. S. (1997) J. Mol. Evol. 44, 440-451[Medline] [Order article via Infotrieve]
  83. Sappington, T. W., and Raikhel, A. S. (1998) Insect Biochem. Mol. Biol. 28, 277-300[CrossRef][Medline] [Order article via Infotrieve]
  84. Kawooya, J. K., Osir, E. O., and Law, J. H. (1986) J. Biol. Chem. 261, 10844-10849[Abstract/Free Full Text]
  85. Kulakosky, P. C., and Telfer, W. H. (1987) Insect Biochem. 19, 367-373
  86. Zhu, J., Indrasith, L. S., and Yamashita, O. (1986) Biochim. Biophys. Acta 882, 427-436
  87. Raikhel, A. S., and Lea, A. O. (1991) Tissue Cell 23, 577-591[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.